Drug Search Results
More Filters [+]

Corticorelin

Alternative Names: corticorelin, acthrel
Latest Update: 2024-06-11
Latest Update Note: Clinical Trial Update

Product Description

Corticorelin is a potent stimulator of adrenocorticotropic hormone (ACTH) release from the anterior pituitary. It is used as a diagnostic agent to evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Corticorelin-ovine-triflutate#section=Biological-Half-Life)

Mechanisms of Action: CRFR Agonist

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | France | Germany | Greece | Korea | Netherlands | Slovenia | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Corticorelin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title